Varenicline

Overview

Varenicline, sold under the brand names Chantix and Champix among others, is a medication used for smoking cessation and for the treatment of dry eye syndrome. It is a nicotinic acetylcholine receptor partial agonist. When activated, this receptor leads to the release of dopamine in the nucleus accumbens, the brain's reward center, thereby reducing cravings and withdrawal symptoms with smoking cessation, although less pronounced than a full agonist (e.g. nicotine).[1–5] WP

Common side effects include nausea, insomnia, abnormal dreams, headache, and nasopharyngitis (inflammation of the nose and throat). Despite these potential adverse effects, varenicline has proven efficacy in helping individuals quit smoking. It is estimated that approximately one in eleven smokers who use varenicline successfully remain abstinent from tobacco at six months.[2][6] WP

It is on the World Health Organization's List of Essential Medicines. The medication is available as a generic medication. In the United States, varenicline was prescribed over 1 million times in 2020, ranking as the 275th most commonly prescribed medication.[7–10] WP

Drug class

Nicotinic agonist WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

Varenicline is indicated for use as an aid to smoking cessation treatment and for the treatment of the signs and symptoms of dry eye disease.[1][3] WP

Varenicline is used to help people stop smoking tobacco (smoking cessation). A meta-analysis found that 20% of people treated with varenicline remain abstinent from smoking at one year. In a 2009 meta-analysis, varenicline was found to be more effective than bupropion (odds ratio 1.40) and nicotine replacement therapies (NRT) (odds ratio 1.56).[11][12] WP

A 2013 Cochrane overview and network meta-analysis concluded that varenicline is the most effective medication for tobacco cessation and that smokers were nearly three times more likely to quit tobacco use while on varenicline than with placebo treatment. Varenicline was more efficacious than bupropion or NRT and as effective as combination NRT for cessation of tobacco smoking.[13][14] WP

Risks and side effects

Side effects

Mild nausea is the most common side effect and is seen in approximately 30% of people taking varenicline, though this rarely (<3%) results in discontinuation of the medication. Other less common side effects include headache, difficulty sleeping, and vivid dreams. Rare side effects reported by people taking varenicline compared to placebo include change in taste, vomiting, abdominal pain, flatulence, and constipation. It has been estimated that for every five subjects taking varenicline at maintenance doses, there will be one event of nausea; and for every 24 of 35 treated subjects, there will be an event of constipation or flatulence. Gastrointestinal side-effects lead to discontinuation of the drug in 2% to 8% of people using varenicline. Incidence of nausea is dose-dependent: incidence of nausea was higher in people taking a larger dose (30%) versus placebo (10%) as compared to people taking a smaller dose (16%) versus placebo (11%).[1][14][15][16] WP

Depression and suicide

In 2007, the US Food and Drug Administration (FDA) announced it had received post-marketing reports of thoughts of suicide and occasional suicidal behavior, erratic behavior, and drowsiness among people using varenicline for smoking cessation. In 2009, the FDA required varenicline to carry a boxed warning that the medication should be stopped if any of these symptoms are experienced.[17] WP

A 2014 systematic review (literature research) did not find evidence of an increased suicide risk. Other analyses have reached the same conclusion and found no increased risk of neuropsychiatric side effects with varenicline. No evidence for increased risks of cardiovascular events, depression, or self-harm with varenicline versus nicotine replacement therapy was found in one post-marketing surveillance study.[13][14][18][19] WP

In 2016, the FDA removed the black box warning. People are still advised to stop the medication if they "notice any side effects on mood, behavior, or thinking."[20][21][22] WP

Cardiovascular disease

In June 2011, the US FDA issued a safety announcement that varenicline may be associated with "a small, increased risk of certain cardiovascular adverse events in people who have cardiovascular disease".[23] WP

A prior 2011 review had found increased risk of cardiovascular events compared with placebo. Expert commentary in the same journal raised doubts about the methodology of the review, concerns which were echoed by the European Medicines Agency and subsequent reviews. Of specific concern were "the low number of events seen, the types of events counted, the higher drop-out rate in people receiving placebo, the lack of information on the timing of events, and the exclusion of studies in which no-one had an event".[24–28] WP

In contrast, multiple recent systematic reviews and meta-analyses have found no increase in overall or serious adverse cardiovascular events (including for individuals at risk of developing cardiovascular disease) associated with varenicline use.[28–31] WP

Pharmacology

Mechanism of action

Varenicline displays full agonism on α₇ nicotinic acetylcholine receptors and is a partial agonist on the α₄β₂, α₃β₄, and α₆β₂ subtypes.[32][33][34] WP

Varenicline's partial agonism on the α₄β₂ receptors rather than nicotine's full agonism produces less effect of dopamine release than nicotine's. This α₄β₂ competitive binding reduces the ability of nicotine to bind and stimulate the mesolimbic dopamine system—similar to the method of action of buprenorphine in the treatment of opioid addiction. However, it is the α₇-pentamer that mediates clinical efficacy at remaining abstinent from nicotine.[14][35] WP

Pharmacokinetics

Most of the active compound is excreted by the kidneys (92–93%) via the organic cation transporter OCT2 (SCL22A2) and may inhibit it at high concentrations. A small proportion is glucuronidated, oxidised, N-formylated or conjugated to a hexose.[36][37] WP

History

History

Use of Cytisus plants as a smoking substitute during World War II led to use as a cessation aid in eastern Europe and extraction of cytisine. Cytisine analogs led to varenicline at Pfizer.[38–42] WP

Varenicline received a priority review by the US FDA in February 2006, shortening the usual ten-month review period to six months because of its demonstrated effectiveness in clinical trials and perceived lack of safety issues. The agency's approval of the drug came in May 2006. In September 2006, it was approved for sale in the European Union.[2][43][44][45] WP

In September 2021, Pfizer announced a recall of "all lots of its anti-smoking treatment, Chantix [varenicline], due to high levels of cancer-causing agents called nitrosamines in the pills". This followed a July 2021 announcement by the FDA that it was "alerting patients and health care professionals to Pfizer's voluntary recall of nine lots of the smoking cessation drug" and further recalls by Pfizer on 19 July and 8 August. In June 2021, Pfizer paused distribution of Chantix worldwide; according to a media statement, "the distribution halt was out of an abundance of caution, pending further testing". According to the Pfizer Inc. 2020 Form 10-K Annual Report, high-revenue products by the company include[d] Chantix/Champix (varenicline) to treat nicotine addiction, which recorded direct product revenues of more than $1 billion in 2019, $919 million in 2020, and $398 million in 2021 (the lower 2021 revenue was due, in part, to the basic product patent expiration for Chantix in the US in November 2020 and in Europe in September 2021, and the aforementioned Pfizer voluntary recall across multiple markets and a global pause in shipments of Chantix.)[46–51] WP

In October 2021, the US FDA approved Oyster Point Pharma to market Tyrvaya as a new route of varenicline administration through nasal spray for the treatment of dry eye disease.[52] WP

Chemistry

Formula

C13H13N3 PC

Molar mass (g/mol)

211.26 PC

IUPAC name (computed by PubChem)

(1S,12R)-5,8,14-triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2,4,6,8,10-pentaene PC

SMILES

C1[C@@H]2CNC[C@H]1C3=CC4=NC=CN=C4C=C23 PC

InChIKey

JQSHBVHOMNKWFT-DTORHVGOSA-N PC

PubChem CID

5310966

IUPAC name

7,8,9,10-Tetrahydro-6,10-methano-6H-pyrazino WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Chantix- varenicline tartrate tablet, film coated Chantix- varenicline tartrate kit
2. Journal / agency Champix EPAR. 17 September 2018
3. Journal / agency Tyrvaya- varenicline spray
4. Other Oyster Point Pharma Announces FDA Approval of Tyrvaya (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease. 18 October 2021
5. Journal / agency Tashkin DP. Smoking Cessation in Chronic Obstructive Pulmonary Disease. Seminars in Respiratory and Critical Care Medicine. August 2015. doi:10.1055/s-0035-1555610 · PMID 26238637
6. Journal / agency Crawford P, Cieslak D. Varenicline for Smoking Cessation. American Family Physician. September 2017. PMID 28925657
7. Other World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). 2023
8. Journal / agency Varenicline tablet, film coated. 27 January 2023
9. Other The Top 300 of 2020
10. Other Varenicline - Drug Usage Statistics
11. Journal / agency Rosen LJ, Galili T, Kott J, Goodman M, Freedman LS. Diminishing benefit of smoking cessation medications during the first year: a meta-analysis of randomized controlled trials. Addiction. May 2018. doi:10.1111/add.14134 · PMID 29377409 · PMC5947828
12. Journal / agency Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduction Journal. September 2009. doi:10.1186/1477-7517-6-25 · PMID 19761618 · PMC2760513
13. Journal / agency Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. The Cochrane Database of Systematic Reviews. May 2013. doi:10.1002/14651858.CD009329.pub2 · PMID 23728690 · PMC8406789
14. Journal / agency Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opinion on Emerging Drugs. June 2014. doi:10.1517/14728214.2014.899580 · PMID 24654737
15. Journal / agency Leung LK, Patafio FM, Rosser WW. Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis. BMC Clinical Pharmacology. September 2011. doi:10.1186/1472-6904-11-15 · PMID 21955317 · PMC3192741
16. Other American Cancer Society. Cancer Drug Guide: Varenicline
17. Journal / agency Public Health Advisory: FDA Requires New Boxed Warnings for the Smoking Cessation Drugs Chantix and Zyban
18. Journal / agency Hughes JR. Varenicline as a Cause of Suicidal Outcomes. Nicotine & Tobacco Research. January 2016. doi:10.1093/ntr/ntu275 · PMID 25572451
19. Journal / agency Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. The Lancet. Respiratory Medicine. October 2015. doi:10.1016/S2213-2600(15)00320-3 · PMID 26355008 · PMC4593936
20. Journal / agency Safety Alerts for Human Medical Products - Chantix (varenicline) and Zyban (bupropion): Drug Safety Communication - Mental Health Side Effects Revised. 16 December 2016
21. Journal / agency Palmer G, Massey V. Electron paramagnetic resonance and circular dichroism studies on milk xanthine oxidase. The Journal of Biological Chemistry. May 1969. doi:10.1186/1753-6561-9-S1-A31 · PMID 4306032 · PMC4306032
22. Journal / agency Yeung E, Bachi B, Long B, Lee J, Chao Y. Varenicline and Depression: a Literature Review. World Journal of Medical Education and Research. 2015
23. Journal / agency FDA Drug Safety Communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. 16 June 2011
24. Journal / agency Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. September 2011. doi:10.1503/cmaj.110218 · PMID 21727225 · PMC3168618
25. Journal / agency Takagi H, Umemoto T. Varenicline: quantifying the risk. CMAJ. September 2011. doi:10.1503/cmaj.111-2063 · PMID 21896705 · PMC3168634
26. Journal / agency Samuels L. Varenicline: cardiovascular safety. CMAJ. September 2011. doi:10.1503/cmaj.111-2073 · PMID 21896709 · PMC3168639
27. Journal / agency European Medicine Agency confirms positive benefit-risk balance for Champix. 21 July 2011
28. Journal / agency Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. May 2012. doi:10.1136/bmj.e2856 · PMID 22563098 · PMC3344735
29. Journal / agency Mills EJ, Thorlund K, Eapen S, Wu P, Prochaska JJ. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. January 2014. doi:10.1161/CIRCULATIONAHA.113.003961 · PMID 24323793 · PMC4258065
30. Journal / agency Pipe AL. Network meta-analysis demonstrates the safety of pharmacotherapy for smoking cessation in cardiovascular patients. Evidence-Based Medicine. October 2014. doi:10.1136/eb-2014-110030 · PMID 24917603
31. Journal / agency Rowland K. ACP Journal Club. Review: Nicotine replacement therapy increases CVD events; bupropion and varenicline do not. Annals of Internal Medicine. April 2014. doi:10.7326/0003-4819-160-8-201404150-02002 · PMID 24733219
32. Journal / agency Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Molecular Pharmacology. September 2006. doi:10.1124/mol.106.025130 · PMID 16766716
33. Journal / agency Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends in Pharmacological Sciences. December 2010. doi:10.1016/j.tips.2010.09.004 · PMID 20965579 · PMC2991594
34. Journal / agency Bordia T, Hrachova M, Chin M, McIntosh JM, Quik M. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum. The Journal of Pharmacology and Experimental Therapeutics. August 2012. doi:10.1124/jpet.112.194852 · PMID 22550286 · PMC3400806
35. Journal / agency Santos JR, Tomaz PR, Scholz JR, Gaya PV, Abe TO, Krieger JE, Pereira AC, Santos PC. Profile of the Nicotinic Cholinergic Receptor Alpha 7 Subunit Gene Expression is Associated with Response to Varenicline Treatment. Genes. July 2020. doi:10.3390/genes11070746 · PMID 32640505 · PMC7397196
36. Journal / agency Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metabolism and Disposition. January 2006. doi:10.1124/dmd.105.006767 · PMID 16221753
37. Journal / agency Highlights of prescribing information - CHANTIX® (varenicline) tablets, for oral use
38. Journal / agency Seeger R. Cytisine as an aid for smoking cessation. Medizinische Monatsschrift für Pharmazeuten. January 1992. PMID 1542278
39. Journal / agency Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ. August 2013. doi:10.1136/bmj.f5198 · PMID 23974638
40. Journal / agency Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD, O'Neill BT. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry. May 2005. doi:10.1021/jm050069n · PMID 15887955
41. Journal / agency Schwartz JL. Review and evaluation of methods of smoking cessation, 1969-77. Summary of a monograph. Public Health Reports. 1979. PMID 515342 · PMC1431736
42. Journal / agency Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Archives of Internal Medicine. 2006. doi:10.1001/archinte.166.15.1553 · PMID 16908787
43. Journal / agency Kuehn BM. FDA speeds smoking cessation drug review. JAMA. February 2006. doi:10.1001/jama.295.6.614 · PMID 16467225
44. Journal / agency FDA Approves Novel Medication for Smoking Cessation. 11 May 2006
45. Journal / agency Drug Approval Package: Chantix (Varenicline) NDA #021928. 16 June 2006
46. Other Pfizer recalls all lots of anti-smoking drug over carcinogen presence. 16 September 2021
47. Journal / agency FDA Updates and Press Announcements on Nitrosamine in in Varenicline. 17 September 2021
48. Other Carcinogen Contamination Halts Sales of Smoking-Cessation Drug. 25 June 2021
49. Other Pfizer Pauses Chantix Distribution After Finding Carcinogen. 24 June 2021
50. Other Pfizer Inc. 2020 Form 10-K Annual Report, 25 February 2021 |access-date=30 December 2022
51. Other Pfizer Inc. 2021 Form 10-K Annual Report, 24 Feb 2022 |access-date=30 December 2022
52. Other Harrison L. FDA Approves First Nasal Spray for Dry Eye. 27 October 2021

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.